Drug intelligence / Profile preview

MEDI9314

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

MEDI9314 is a fully human monoclonal antibody that acts as an antagonist of the interleukin-4 receptor alpha (IL-4Rα). It was developed by MedImmune (now part of AstraZeneca) for the treatment of atopic dermatitis. The drug functions by inhibiting IL-4Rα, thereby blocking signaling from both interleukin-4 and interleukin-13, which are key cytokines involved in type 2 inflammatory responses. Clinical development reached phase 1 trials in healthy volunteers but was discontinued after this stage[1][2][3][4].

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on MEDI9314.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI9314.

Explore the full profile